Last reviewed · How we verify

Camzyos — Competitive Intelligence Brief

Camzyos (MAVACAMTEN) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cardiac Myosin Inhibitor [EPC]. Area: Cardiovascular.

marketed Cardiac Myosin Inhibitor [EPC] cardiac myosin Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Camzyos (MAVACAMTEN) — Bristol-Myers Squibb. Mavacamten selectively inhibits cardiac myosin, reducing force-producing cross-bridge formation and improving cardiac function in HCM.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Camzyos TARGET MAVACAMTEN Bristol-Myers Squibb marketed Cardiac Myosin Inhibitor [EPC] cardiac myosin 2022-01-01
Omecamtiv Mecarbil (OM) Omecamtiv Mecarbil (OM) Cytokinetics phase 3 Cardiac myosin activator Cardiac myosin
TNX-103 TNX-103 Tenax Therapeutics, Inc. phase 3 Cardiac myosin inhibitor Cardiac myosin
Camzyos MYK-461 Myokardia Inc marketed Cardiac Myosin Inhibitor [EPC] Myosin-7 2022-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

Sponsor landscape (Cardiac Myosin Inhibitor [EPC] class)

  1. Bristol-Myers Squibb · 1 drug in this class
  2. Myokardia Inc · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Camzyos — Competitive Intelligence Brief. https://druglandscape.com/ci/mavacamten. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: